Skip to main content
. Author manuscript; available in PMC: 2018 Jan 15.
Published in final edited form as: Cancer Res. 2016 Oct 13;77(2):520–531. doi: 10.1158/0008-5472.CAN-16-1140

Figure 7. Rapamycin and DD synergize in reducing NM001 B cell lymphoma but not Jurkat CD4+ T cell lymphoma cell numbers in vitro.

Figure 7

Jurkat CD4+ T cell lymphoma (A) and NM001 B lymphoma (B) cell lines were treated in vitro with 0, 100 or 200 pg/ml rapamycin for 48 hrs. Representative flow cytometry dot plots of CD25 and CD122 expression. CD25 mean fluorescence intensity (MFI) of the total live gate indicated in the lower right. NM001 B lymphoma (C) and Jurkat cell lines (D) were cultured for 5 days in vitro in control medium (Con), 100 pg/ml rapamycin (RA), 250 ng/ml (DD) or both and cell numbers counted. (E) NM001 B lymphoma cells were cultured for 5 days in vitro in control medium (Con), 500 pg/ml temsirolimus (TEM), 250 ng/ml (DD) or both. Viable cells were counted. P value, unpaired t test. Error bars, mean ± SEM.